Extension of Time to File SOU

CIXXORD

Hospira, Inc.

Request for Extension of Time to File a Statement of Use

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
PTO Form 1581 (Rev 09/2005)
OMB No. 0651-0054 (Exp 12/31/2020)

Request for Extension of Time to File a Statement of Use
(15 U.S.C. Section 1051(d))


The table below presents the data as entered.

Input Field
Entered
SERIAL NUMBER 88265786
LAW OFFICE ASSIGNED LAW OFFICE 126
MARK SECTION
MARK CIXXORD (see, http://uspto.report/TM/88265786/mark.png)
STANDARD CHARACTERS YES
USPTO-GENERATED IMAGE YES
LITERAL ELEMENT CIXXORD
OWNER SECTION (current)
NAME Hospira, Inc.
MAILING ADDRESS 275 N. Field Dr.
CITY Lake Forest
STATE Illinois
ZIP/POSTAL CODE 60045
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY United States
PHONE 212-733-0086
EMAIL XXXX
OWNER SECTION (proposed)
NAME Hospira, Inc.
MAILING ADDRESS 275 N. Field Dr.
CITY Lake Forest
STATE Illinois
ZIP/POSTAL CODE 60045
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY United States
PHONE  
EMAIL XXXX
CORRESPONDENCE INFORMATION (current)
NAME Heather A. McDonald
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE deadlinesipnyo@pfizer.com
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) NOT PROVIDED
CORRESPONDENCE INFORMATION (proposed)
NAME Heather A. McDonald
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE deadlinesipnyo@pfizer.com
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) NOT PROVIDED
DOCKET/REFERENCE NUMBER T425491
GOODS AND/OR SERVICES SECTION
INTERNATIONAL CLASS 005
CURRENT IDENTIFICATION Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, immunological, infectious, inflammatory, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, ophthalmological, psychiatric, respiratory, urogenital, urological and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, liver disorders, erectile dysfunction, sexual dysfunction, cancer, pain and diabetes; pharmaceutical preparations, namely, antifungal preparations, dermatological preparations and smoking cessation preparations; vaccines for human use
GOODS OR SERVICES KEEP ALL LISTED
EXTENSION SECTION
EXTENSION NUMBER 2
ONGOING EFFORT product or service research or development
ALLOWANCE MAIL DATE 07/09/2019
STATEMENT OF USE NO
PAYMENT SECTION
NUMBER OF CLASSES 1
SUBTOTAL AMOUNT [EXTENSION FEE] 125
TOTAL AMOUNT 125
SIGNATURE SECTION
SIGNATURE /heather a mcdonald/
SIGNATORY'S NAME Heather A. McDonald
SIGNATORY'S POSITION Attorney of record, NY bar member
DATE SIGNED 05/07/2020
SIGNATORY'S PHONE NUMBER 2127330412
FILING INFORMATION
SUBMIT DATE Fri May 08 10:30:03 ET 2020
TEAS STAMP USPTO/ESU-XXX.XXX.XX.XXX-
20200508103003702918-8826
5786-710907f752f2fd187fb6
3b6d88414f0da2f1165d3c6cf
a335fcea14f9a5cfe91ca-DA-
30036024-2020050716091887
5264



Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
PTO Form 1581 (Rev 09/2005)
OMB No. 0651-0054 (Exp 12/31/2020)


SOU Extension Request
(15 U.S.C. Section 1051(d))


To the Commissioner for Trademarks:

MARK: CIXXORD (see, http://uspto.report/TM/88265786/mark.png)
SERIAL NUMBER: 88265786

OWNER AND/OR ENTITY INFORMATION
The owner proposes to amend the following:
Current: Hospira, Inc., having an address of
      275 N. Field Dr.
      Lake Forest, Illinois 60045
      United States
      Phone: 212-733-0086
      Email: XXXX
Proposed: Hospira, Inc., having an address of
      275 N. Field Dr.
      Lake Forest, Illinois 60045
      United States
      Phone:
      Fax:
      Email: XXXX

The owner requests a six-month extension of time to file the Statement of Use under 37 C.F.R. Section 2.89 in this application.    The Notice of Allowance mailing date was 07/09/2019.

For International Class 005:
Current identification: Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, immunological, infectious, inflammatory, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, ophthalmological, psychiatric, respiratory, urogenital, urological and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, liver disorders, erectile dysfunction, sexual dysfunction, cancer, pain and diabetes; pharmaceutical preparations, namely, antifungal preparations, dermatological preparations and smoking cessation preparations; vaccines for human use

For a trademark/service mark: The applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all of the goods/services listed in the Notice of Allowance or as subsequently modified for this specific class; for a collective/certification mark: the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the mark in commerce on or in connection with the goods/services/collective membership organization listed in the Notice of Allowance, or as subsequently modified for this specific class.


This is the second extension request. The applicant has made the following ongoing efforts to use the mark in commerce on or in connection with each of those goods/services covered by the extension request: product or service research or development

Correspondence Information (current):
      Heather A. McDonald
      PRIMARY EMAIL FOR CORRESPONDENCE: deadlinesipnyo@pfizer.com
      SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): NOT PROVIDED

Correspondence Information (proposed):
      Heather A. McDonald
      PRIMARY EMAIL FOR CORRESPONDENCE: deadlinesipnyo@pfizer.com
      SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): NOT PROVIDED


Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the owner/holder and the owner's/holder's attorney, if appointed, and that all official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS).





A fee payment in the amount of $125 will be submitted with the form, representing payment for 1 class.


Declaration

STATEMENTS: The signatory believes that: the applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all the goods/services under Section 1(b) in the notice of allowance or as subsequently modified, or, if applicable, the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the mark in commerce on or in connection with all the goods/services/collective membership organization under Section 1(b) in the notice of allowance or as subsequently modified; and that to the best of the signatory's knowledge and belief, no other persons, except, if applicable, members and concurrent users, have the right to use the mark in commerce, either in the identical form or in such near resemblance as to be likely, when used on or in connection with the goods/services/collective membership organization of such other persons, to cause confusion or mistake, or to deceive.

DECLARATION: The signatory being warned that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001, and that such willful false statements and the like may jeopardize the validity of the application or submission or any resulting registration, declares that all statements made of his/her own knowledge are true and that all statements made on information and belief are believed to be true.


Signature: /heather a mcdonald/      Date Signed: 05/07/2020
Signatory's Name: Heather A. McDonald
Signatory's Position: Attorney of record, NY bar member
Signatory's Phone: 2127330412

RAM Sale Number: 88265786
RAM Accounting Date: 05/08/2020

Serial Number: 88265786
Internet Transmission Date: Fri May 08 10:30:03 ET 2020
TEAS Stamp: USPTO/ESU-XXX.XXX.XX.XXX-202005081030037
02918-88265786-710907f752f2fd187fb63b6d8
8414f0da2f1165d3c6cfa335fcea14f9a5cfe91c
a-DA-30036024-20200507160918875264




uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.

© 2024 USPTO.report | Privacy Policy | Resources | RSS Feed of Trademarks | Trademark Filings Twitter Feed